
|Articles|October 20, 2015
Efficacy of Ozurdex in DME in the real world clinical setting-Leowenstein interview
Professor Anat Lowenstein talks about the impact of Ozurdex in treating diabetic macular edema (DME) in the real world clinical setting. This renowned expert in the DME field, explores what the licensing of Ozurdex in DME means to both patients and retinal specialists when treating this potentially blinding condition.
Advertisement
Redirect to video article
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
3
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
4
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA
5















































.png)


